Related references
Note: Only part of the references are listed.ACC/AHA lipid guidelines: Personalized care to prevent cardiovascular disease
Cara Reiter-Brennan et al.
CLEVELAND CLINIC JOURNAL OF MEDICINE (2020)
High Prevalence and Gender-Related Differences of Gastrointestinal Manifestations in a Cohort of DM1 Patients: A Perspective, Cross-Sectional Study
Alessia Perna et al.
FRONTIERS IN NEUROLOGY (2020)
Treatment of Dyslipidemia in Common Liver Diseases
Elizabeth K. Speliotes et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Epidemiology of non-alcoholic fatty liver disease-related hepatocellular carcinoma and its implications
Sui-Weng Wong et al.
JGH OPEN (2018)
Dyslipidemia in Special Ethnic Populations
Jia Pu et al.
CARDIOLOGY CLINICS (2015)
Statin Intolerance
David H. Fitchett et al.
CIRCULATION (2015)
Metabolic syndrome in patients with myotonic dystrophy type 1
Milorad Vujnic et al.
MUSCLE & NERVE (2015)
The spectrum of statin myopathy
Payam Mohassel et al.
CURRENT OPINION IN RHEUMATOLOGY (2013)
From NAFLD to NASH and HCC: Pathogenetic Mechanisms and Therapeutic Insights
Samuele De Minicis et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Characteristics of Japanese Duchenne and Becker muscular dystrophy patients in a novel Japanese national registry of muscular dystrophy (Remudy)
Harumasa Nakamura et al.
ORPHANET JOURNAL OF RARE DISEASES (2013)
Selective Hepatic Insulin Resistance, VLDL Overproduction, and Hypertriglyceridemia
Janet D. Sparks et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
The myotonic dystrophies: molecular, clinical, and therapeutic challenges
Bjarne Udd et al.
LANCET NEUROLOGY (2012)
Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity
Giovanni Musso et al.
ANNALS OF MEDICINE (2011)
Increased Activity of Serum γ-Glutamyltransferase in Myotonic Dystrophy
TAPANI RÖNNEMAA et al.
ACTA MEDICA SCANDINAVICA (2010)
Triglycerides and non-high-density lipoprotein cholesterol and the incidence of cardiovascular disease in an urban Japanese cohort: The Suita study
Tomonori Okamura et al.
ATHEROSCLEROSIS (2010)
Triglycerides and gallstone formation
A. H. M. Smelt
CLINICA CHIMICA ACTA (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
FREQUENCY AND PREDICTORS OF NONALCOHOLIC FATTY LIVER DISEASE IN MYOTONIC DYSTROPHY
Kenneth Shieh et al.
MUSCLE & NERVE (2010)
A cross-sectional study for glucose intolerance of myotonic dystrophy
Tsuyoshi Matsumura et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2009)
Patient Registries and Trial Readiness in Myotonic Dystrophy – TREAT-NMD/Marigold International Workshop Report
Rachel Thompson et al.
NEUROMUSCULAR DISORDERS (2009)
Laboratory abnormalities in ambulatory patients with myotonic dystrophy type 1
Chad R. Heatwole et al.
ARCHIVES OF NEUROLOGY (2006)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
Clinical and molecular aspects of the myotonic dystrophies: A review
L Machuca-Tzili et al.
MUSCLE & NERVE (2005)
Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy
RS Savkur et al.
NATURE GENETICS (2001)
Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
JI Cleeman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Share Paper
